These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34191656)

  • 21. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disproportionality Analysis of Lenvatinib-Caused Gastrointestinal Perforation in Cancer Patients: A Pharmacovigilance Analysis Based on the US Food and Drug Administration Adverse Event Reporting System.
    Zhou J; Wei Z; Zheng Y; Xie H; Cao W; Cai X; Huang J; Wu X
    J Clin Pharmacol; 2023 Oct; 63(10):1133-1140. PubMed ID: 37474123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
    Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
    Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
    Caldito NG; Shirani A; Salter A; Stuve O
    Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
    Shin H; Lee S
    BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
    Shu Y; He X; Wu P; Liu Y; Ding Y; Zhang Q
    Front Public Health; 2022; 10():996179. PubMed ID: 36339230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case-control pharmacovigilance study of TNF-alpha inhibitors and interleukin inhibitors on tuberculosis, Candida, lymphoma and suicidality using the FAERS database (2014-2020).
    Arcuri D; Kaouache M; Lagacé F; Sasseville D; Litvinov I
    J Am Acad Dermatol; 2023 Sep; 89(3):619-621. PubMed ID: 37245836
    [No Abstract]   [Full Text] [Related]  

  • 31. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
    Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
    Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
    Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
    Wei C; Liu Y; Jiang A; Wu B
    Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
    Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
    Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database.
    Yang X; Yang B; Li D; Pan W; Tong Q; Wang L; Chen D; Fu C
    Clin Drug Investig; 2024 Mar; 44(3):199-207. PubMed ID: 38376794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022.
    Huang H; Li L; Wu M; Liu Z; Zhao Y; Peng J; Ren X; Chen S
    BMC Pharmacol Toxicol; 2023 Dec; 24(1):73. PubMed ID: 38049920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases.
    Shiraishi C; Hirai T; Ogura T; Iwamoto T
    Anticancer Res; 2023 Feb; 43(2):883-891. PubMed ID: 36697083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.